Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive

Today, 5:40 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27)

AFIB

1 minute read

Legal
News

Eagle Pharma Reports District Court Held That Co.’s Proposed Vaspressin Product Does Not Infringe On Any Patents Par Asserted Against Co.

By Benzinga Newsdesk

Today, 5:40 AM

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product

EGRX

1 minute read

Eagle Pharmaceuticals Granted Additional Patent For Bendamustine Franchise

By Bill Haddad

Today, 5:40 AM

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled

EGRX

4 minute read

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug

By Shanthi Rexaline

Today, 5:40 AM

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24)

AGEN

4 minute read

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement With Combioxin SA For Phase 2b/3 Antitoxin Agent CAL02 In Development For Combination Use With Antibiotics For Treatment Of Severe Pneumonia

By Bill Haddad

Today, 5:40 AM

-- CAL02 neutralizes toxic virulence effectors ("VEs") produced by bacteria; VEs play a decisive role in the development of long-term, severe and fatal pneumonia complications -- -- Results of

EGRX

1 minute read

Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus

By Vandana Singh

Today, 5:40 AM

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its…

EGRX

1 minute read

Recap: Eagle Pharmaceuticals Q2 Earnings

By Benzinga Insights

Today, 5:40 AM

Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0.93, which beat the estimate of $0.80.

EGRX

1 minute read

Eagle Pharmaceuticals Q2 Adj. EPS $0.95 Beats $0.80 Estimate, Sales $48.10M Beat $45.86M Estimate

By Bill Haddad

Today, 5:40 AM

Eagle Pharmaceuticals (NASDAQ:EGRX) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.80 by 18.75 percent. This is a 66.67 percent increase over earnings of $0.57 per share

EGRX

5 minute read

Eagle Pharmaceuticals Announces Licensing Agreement With AOP Orphan For US Commercial Rights To Landiolol, A Beta-1 Adrenergic Blocker; Co. To Make $5M Upfront Payment And Potential Milestone Payments

By Bill Haddad

Today, 5:40 AM

-- Eagle poised to facilitate regulatory pathway for approval in the U.S. based on existing data from Japanese and European studies, with no additional clinical work expected – -- Anticipates filing new drug

EGRX

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 5:40 AM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM